Diabetes
Commentary
Once-Weekly Insulin: A Game-Changer for Primary Care
“Game-changer” is an overused term, but from the perspective of primary care, it applies to once-weekly insulin.
From the Journals
The Uneven Surge in Diabetes in the United States
The overall prevalence of diabetes increased by 18.6% from 2012 to 2022, with the highest prevalence observed among non-Hispanic Black individuals...
Latest News
Healthy Lifestyle Mitigates Brain Aging in Diabetes
A healthy lifestyle attenuated the association between diabetes and a higher brain age gap.
Latest News
Environmental, Metabolic Factors Driving Global Rise in Stroke
“The global growth of the number of people who develop stroke and died from or remain disabled by stroke is growing fast, strongly suggesting that...
Latest News
Feds Sue Three Biggest Pharmacy Benefit Managers Over Insulin Costs
The FTC has filed suit against three PBMs alleging that they directed patients to higher priced insulin treatments.
Latest News
Semaglutide Bests Liraglutide in Long-Term Weight Loss
The current paper gives patients and clinicians reasonable expectations of the trajectory of weight loss when the drugs are prescribed for...
Latest News
Controlling Six Risk Factors Can Combat CKD in Obesity
Optimal management of blood pressure, A1c levels, low-density lipoprotein cholesterol (LDL-C), albuminuria, smoking, and physical activity may...
Latest News
Guidance Will Aid Pediatric to Adult Diabetes Care Transfer
The care transition period is critical because “adolescents and young adults are the least likely of all age groups to achieve glycemic targets...
Latest News
Short Steroid Treatment May Raise Diabetes Risk: Study
“We know that this is an issue, but we didn’t necessarily know numerically how significant it was.”
Conference Coverage
Will New Obesity Drugs Make Bariatric Surgery Obsolete?
“Efficacy of drugs is measured in weeks or months, whereas efficacy of surgery is measured in decades of durability.”
Latest News
SGLT2 Inhibitor Reduces Risk for Neurodegenerative Diseases in T2D
Those receiving SGLT2i treatment had a 21% reduced risk for all-cause dementia and a 22% reduced risk for all-cause dementia and Parkinson’s...